期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Early Quality Life Impairment in Alzheimer Disease’s Patients in Geriatric Department: About 214 Cases in Pitié Salpêtrière Hospital of Paris (France)
1
作者 Andia Abdoulkader Audrey Rouet +4 位作者 Benedicte Dieudonné Jacque Boaddert Charlotte Tomeo Sandrine Greffard Marc Verny 《Open Journal of Internal Medicine》 2024年第1期30-42,共13页
Alzheimer’s disease (AD) is the most common neurodegenerative disease causing an alteration of life quality in the terminal stage. The purpose was to report 14 years of experience about the early impact on the qualit... Alzheimer’s disease (AD) is the most common neurodegenerative disease causing an alteration of life quality in the terminal stage. The purpose was to report 14 years of experience about the early impact on the quality of life of patients with AD. Methodology: Descriptive retrospective study over 14 years in the geriatric department of Pitié Salpêtrière Hospital, using the activity of daily living, Instrumental activity of daily living, neuropsychological inventory and Hoen Yahr scale evaluated at the time of diagnosis of AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer Disease’s and Related Disorders Association diagnostic criteria. Results: A total of 214 exploitable files had been listed. At the moment of diagnosis, the mean age was 82.1 years with extremes 68 to 95 with sex ratio 1.6 in women’s favor. The mean socio-cultural level was 4.9 with extremes about 0 to 7. There was poly pathology with a mean Cumulative Illness Rate Scale = 4.6 with extremes 0 to 16. the mean cognitive status was moderate = 22.5 with extremes 0 to 30. Quality life showed moderate impairment of IADL = 9.2 with extreme 3 to 11 compared to activity of daily living. The activity of daily living was more affected in 68 - 80-year-olds, while poly pathology impacted more on IADL in men. The cognitive impairment was more deficient in IADL when the MMSE test was low. The common disorders at the NPI were psychological, behavioral and psychotic. Conclusion: At the early diagnosis of Alzheimer’s Disease cognitive deficiencies were predominant and influenced on global Instrumental activity and psychological, behavioral disorders. 展开更多
关键词 Alzheimer’s Disease Iadl adl npi PARIS FRANCE
暂未订购
艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病的疗效观察 被引量:14
2
作者 李超 狄丽丽 +2 位作者 佟久芬 高利常 李欣 《药物评价研究》 CAS 2020年第12期2481-2484,共4页
目的分析艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病患者的临床疗效。方法选择2016年7月—2018年7月开滦总医院收治的老年阿尔茨海默病患者57例作为研究对象,根据治疗方法差异将患者分为对照组(30例)和观察组(27例)。对照组口服奥拉西... 目的分析艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病患者的临床疗效。方法选择2016年7月—2018年7月开滦总医院收治的老年阿尔茨海默病患者57例作为研究对象,根据治疗方法差异将患者分为对照组(30例)和观察组(27例)。对照组口服奥拉西坦胶囊,0.8 g/次,3次/d。观察组在对照组基础上口服艾地苯醌片,30 mg/次,3次/d。3个月为1疗程,两组均治疗2个疗程。观察两组患者的临床疗效,同时比较两组治疗前后的蒙特利尔认知评估量表(MoCA)评分、日常生活能力量表(ADL)评分和神经精神科量表(NPI)评分。结果治疗后,观察组总有效率为85.19%,显著高于对照组的60.00%,两组比较具有统计学意义(P<0.05)。随着治疗时间延长,两组患者MoCA评分均显著提升(P<0.05),但观察组MoCA评分明显高于同时期对照组(P<0.05)。随着治疗时间延长,两组患者ADL评分均显著降低(P<0.05),但观察组ADL评分明显低于同时期对照组(P<0.05)。治疗后,观察组患者NPI评分低于治疗前(P<0.05),且观察组治疗后NPI评分显著低于对照组(P<0.05)。结论艾地苯醌联合奥拉西坦治疗老年阿尔茨海默病效果显著,且能有效改善患者认知及行为能力,改善精神症状,同时用药安全性较高。 展开更多
关键词 艾地苯醌 奥拉西坦 老年阿尔茨海默病 蒙特利尔认知评估量表 日常生活能力量表 神经精神科量表
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部